Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Total Debt: 2010-2025

Historic Total Debt for Cytokinetics (CYTK) over the last 10 years, with Sep 2025 value amounting to $176.0 million.

  • Cytokinetics' Total Debt rose 66.82% to $176.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.0 million, marking a year-over-year increase of 66.82%. This contributed to the annual value of $104.7 million for FY2024, which is 53.00% up from last year.
  • Latest data reveals that Cytokinetics reported Total Debt of $176.0 million as of Q3 2025, which was down 0.36% from $176.7 million recorded in Q2 2025.
  • Over the past 5 years, Cytokinetics' Total Debt peaked at $176.7 million during Q2 2025, and registered a low of $46.5 million during Q1 2021.
  • Moreover, its 3-year median value for Total Debt was $104.7 million (2024), whereas its average is $99.8 million.
  • As far as peak fluctuations go, Cytokinetics' Total Debt decreased by 4.18% in 2023, and later spiked by 73.31% in 2024.
  • Quarterly analysis of 5 years shows Cytokinetics' Total Debt stood at $47.4 million in 2021, then surged by 36.74% to $64.8 million in 2022, then increased by 5.71% to $68.5 million in 2023, then spiked by 53.00% to $104.7 million in 2024, then spiked by 66.82% to $176.0 million in 2025.
  • Its Total Debt was $176.0 million in Q3 2025, compared to $176.7 million in Q2 2025 and $105.0 million in Q1 2025.